MedTrace Logo

A Study of Dayingpian Treating Bipolar Disorder

NCT05247593 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 308

Last updated 2022-10-19

No results posted yet for this study

Summary

The main purpose of this cohort study is to evaluate the efficiency and safety of Dayingpian to provide evidence-based medical evidence for the subsequent drug development.

Conditions

Interventions

DRUG

Dayingpian

The actual dosage of Dayingpian is adjusted according to the patient's condition. The recommended dosage of Dayingpian is 5-10 tablets each time, 2-3 times a day.

DRUG

conventional mood stabilizers

Patients in the group are treated with the standard level of conventional mood stabilizers provided by psychiatrists according to treatment guidelines for bipolar disorder.

Sponsors & Collaborators

  • Shanghai Mental Health Center

    lead OTHER

Eligibility

Min Age
14 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2024-06-30
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05247593 on ClinicalTrials.gov